Following the conclusion of a Phase I proof-of-mechanism study of its investigational medicine TAK-062, Takeda has announced its acquisition of PvP Biologics.
TAK-062 is meant to be used for providing the treatment of uncontrolled celiac disease. This is highly potent super glutenase, a protein that degrades ingested gluten that was computationally engineered to treat coeliac disease.
Asit Parikh, head of gastroenterology therapeutic area unit at Takeda, says:
“Many people living with celiac disease manage their symptoms by following a gluten-free diet, but there is no treatment for those who continue to experience severe symptoms. PvP Biologics’ work demonstrated that TAK-062 is a highly targeted therapy that could change the standard of care in celiac disease. We are now applying our deep expertise in gastrointestinal diseases to advance the clinical study of TAK-062 and TAK-101, two programs with different modalities that have both demonstrated clinical proof of mechanism.”
Celiac disease is defined as a genetically driven chronic immune-mediated disorder. In this disease, abnormal immune responses to gluten peptides damage the small intestinal mucosal. The symptoms of Celiac disease include abdominal pain, diarrhoea, nausea, and vomiting.